Azithromycin in Feline GI Practice: A Practical Look at Its Prokinetic Potential

Managing feline gastrointestinal cases can often test a clinician’s patience. A cat that continues vomiting, refuses food, or regurgitates despite antiemetics and supportive care may leave veterinarians searching for additional answers. In many such cases, gastric dysmotility (GD) deserves closer attention¹. 

GD is increasingly recognized as an important factor complicating gastrointestinal and systemic illness in cats. However, diagnosis remains difficult because the clinical signs are vague and easily confused with stress, hospitalization effects, or concurrent disease. Traditional techniques for evaluating gastric motility are also difficult to apply routinely in clinical settings, which has historically limited both diagnosis and treatment decisions¹. 

The Search for Better Prokinetic Options 

Current treatment choices for feline gastric motility disorders are relatively limited.2 In addition, there is still a lack of robust feline-specific evidence regarding the in vivo effects of many prokinetic agents². As a result, clinicians frequently rely on extrapolated data or anecdotal protocols. 

Recent research has focused on motilin receptors as a therapeutic target. Although cats differ from dogs and humans in their gastrointestinal motility patterns, motilin receptors are still present within the feline gastric antrum and duodenum¹. Studies have shown that motilin agonists can stimulate GI motility in cats, supporting their potential role in managing GD¹. 

This has renewed interest in macrolide antibiotics such as erythromycin and azithromycin. 

What the Study Found 

Using a validated ultrasonographic technique to evaluate gastric emptying and antral motility, researchers compared azithromycin, erythromycin, and placebo in healthy cats^1,3. The study demonstrated that azithromycin significantly accelerated gastric emptying in the later phases of digestion, producing effects similar to erythromycin. 

One particularly interesting finding was that improved gastric emptying occurred even though measurable increases in antral motility were only modest. This suggests that gastric emptying reflects overall coordination between the gastric antrum, pylorus, and duodenum rather than simply stronger contractions¹. 

For clinicians, this means that cats with functional gastric delay may still benefit from prokinetic therapy even when obvious motility abnormalities are difficult to identify. 

Why Azithromycin Stands Out 

Azithromycin appears especially attractive for feline practice because of its pharmacokinetic advantages. 

Compared with erythromycin¹: 

• Oral bioavailability is significantly better in cats  

• The elimination half-life is substantially longer 

• Less frequent dosing improves owner compliance  

• Injectable and oral forms are widely available  

• Reduced dosing frequency may lower medication-related stress in cats  

In real-world practice, these factors matter. Many owners struggle with administering repeated medications to cats, especially in chronic GI cases. A drug requiring fewer doses can improve compliance and overall case management¹. 

Another important point is that erythromycin serum levels may not accurately reflect tissue concentrations, which could explain why some cats still respond clinically despite low detectable serum concentrations. 

Balancing Benefits With Stewardship 

Despite the promising findings, clinicians should approach azithromycin thoughtfully. The use of antibiotics for noninfectious conditions raises valid concerns regarding antimicrobial resistance. There is also growing awareness about the potential impact of antibiotics on the gut microbiome^1,4,5. 

Although feline-specific microbiome studies are lacking, pediatric human data have shown temporary reductions in microbial diversity following azithromycin administration⁶. These concerns should be weighed carefully before initiating prolonged or repeated treatment. 

The study also had limitations. Cats included were healthy research animals rather than clinical GD patients, and dosing protocols were extrapolated from human medicine and pharmacokinetic data rather than established veterinary guidelines. 

Moving Toward Smarter GI Management 

For veterinarians managing difficult feline GI cases, the key message is that persistent vomiting and poor appetite may sometimes reflect impaired gastric emptying rather than uncontrolled nausea alone. 

Azithromycin may eventually become a valuable addition to feline prokinetic therapy because of its practical dosing advantages and demonstrated effects on gastric emptying. However, until more clinical data becomes available, careful patient selection and responsible antimicrobial use should remain central to decision-making. 

Reference 

1. Rutherford S, Gaschen F, Husnik R, Fletcher J, Gaschen L. Ultrasonographic evaluation of the effects of azithromycin on antral motility and gastric emptying in healthy cats. Journal of veterinary internal medicine. 2022 Mar;36(2):508-14. https://academic.oup.com/jvim/article-pdf/36/2/508/66666515/jvim16385.pdf 

2. Husnik R, Gaschen FP, Fletcher JM, Gaschen L. Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats. Journal of veterinary internal medicine. 2020 Jul;34(4):1440-6. https://academic.oup.com/jvim/article-pdf/34/4/1440/66660463/jvim15787.pdf 

3. Husnik R, Fletcher JM, Gaschen L, Gaschen FP. Validation of ultrasonography for assessment of gastric emptying time in healthy cats by radionuclide scintigraphy. Journal of veterinary internal medicine. 2017 Mar;31(2):394-401. https://academic.oup.com/jvim/article-pdf/31/2/394/66669133/jvim14674.pdf 

4. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ. Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet. 2016 Jan 9;387(10014):176-87. https://courses.edx.org/assets/courseware/v1/3ef0ee294452911304073dcedcf14d8a/c4x/KIx/KIGlobalHx/asset/Lancet_2.pdf 

5. Whittemore JC, Stokes JE, Price JM, Suchodolski JS. Effects of a synbiotic on the fecal microbiome and metabolomic profiles of healthy research cats administered clindamycin: a randomized, controlled trial. Gut Microbes. 2019 Jul 4;10(4):521-39. https://www.tandfonline.com/doi/pdf/10.1080/19490976.2018.1560754 

6. Wei S, Mortensen MS, Stokholm J, Brejnrod AD, Thorsen J, Rasmussen MA, Trivedi U, Bisgaard H, Sørensen SJ. Short-and long-term impacts of azithromycin treatment on the gut microbiota in children: a double-blind, randomized, placebo-controlled trial. EBioMedicine. 2018 Dec 1;38:265-72. https://www.thelancet.com/article/S2352-3964(18)30539-5/pdf